

Supplementary Table 1. Summary of Study-Level Characteristics and Key Outcomes

Ref.	NLR Cutoff(s) U	Outcome/ Endpoint	ACM HR	CVM HR	ACM OR	CVM OR	Adjusted Variables
			(95%CI, p)	(95%CI, p)	(95%CI, p)	(95%CI, p)	
Erdem <i>et al</i> [13]	< 3.48, ≥ 3.48	ACM	NA	NA	18.830 (1.022–346.903), $P = 0.048$	NA	NA
Abe <i>et al</i> [14]	1.19-2.78, 2.89-3 4.66-10.75, > 3.72	ACM	NA	NA	NA	NA	Age, gender, diabetes
Neuen <i>et al</i> [15]	< 3, > 3	ACM and CVM	1.400 (1.253–1.564), $P =$	1.300 (1.204–1.404), $P = 0$	NA	NA	Age, gender, diabetes, and h
Ouellet <i>et al</i> [16]	< 2.38,	ACM	1.690 (1.120–2.550), $P =$	NA	NA	NA	Age, gender, serum albumin access type, diabetes, car obstructive pulmonary HIV/AIDS, ischemic he myocardial infarction, con

							failure
Yaprak <i>et al</i> [17]	> 2.52	ACM	1.536 (0.387–6.098), <i>P</i> =	NA	NA	NA	NA
Sato <i>et al</i> [18]	< 3.5, ≥ 3.5, > 4.11	ACM	1.280 (1.022–1.603), <i>P</i> =	NA	NA	NA	Age, sex, vascular access type, albumin, creatinine, hemoglobin, intact parathyroid hormone, low-density lipoprotein cholesterol, calcium, congestive heart failure, chronic kidney disease, ejection fraction, angiotensin receptor blocker/angiotensin-converting enzyme inhibitor use, neutrophil-lymphocyte ratio


Li <i>et al</i> [19]	> 3.5	ACM and CVM	1.695 (1.288–2.231), $P = 0.001$	1.379 (1.162–1.637), $P = 0.001$	NA	NA	Age, gender, diabetes, hemodialysis duration, lipoprotein cholesterol, high-density lipoprotein cholesterol, C-reactive protein, pulse pressure, left ventricular mass index, plasma homocysteine, carotid intima-media thickness ≥ 1.2 mm)
Xiang <i>et al</i> [20]	< 2.72, 2.72-3.75, > 3.75	ACM and CVM	NA	NA	NA	NA	Age, sex, hemodialysis duration, cardiovascular disease history, hypertension, body mass index, hemoglobin, serum albumin, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, calcium, phosphate, parathyroid hormone, serum parathyroid hormone-related protein, white blood cells, lymphocytes, monocytes, high-sensitivity C-reactive protein

Woziwodzka <i>et al</i> [21]	< 3.9, > 3.9	ACM	2.400 (1.170–4.922), $P =$	NA	NA	NA	Age, gender, diabetes, hemo
Balboul <i>et al</i> [22]	Baseline NLR varying NLR	ACM and CVM	1.035 (0.996–1.075), $P =$	1.013 (0.940–1.091), $P = 0$	NA	NA	Age, sex, dialysis vintage, comorbidity index, vascular dialysis adequacy (Kt/V), white blood cells, triglycer transaminase, uric acid nutritional risk index, C-react
Kular <i>et al</i> [23]	> 6.9	ACM	1.030 (1.010–1.050), $P =$	NA	NA	NA	NA
Oguz <i>et al</i> [24]	> 5.17	ACM	NA	NA	21.900 (2.920–164.241), $P = 0.003$	NA	NA

Zhang <i>et al</i> [25]	≤ 3.42 vs > 3.42	ACM and CVM	NA	NA	2.329 (1.264–4.292), $P = 0.007$	1.430 (0.689-2.9	Age, sex, neutrophils, platelets, hemoglobin, serum cholesterol, triglycerides, phosphate, C-reactive protein
Lano <i>et al</i> [6]	< 3.49 , > 3.49	ACM and CVM and mortality	NA	NA	1.130 (1.012–1.262), $P = 0.030$	1.11 (1.006-1.22	NA
Wang <i>et al</i> [26]	N/A	Frailty and CVM	NA	NA	7.554 (3.257–17.522), $P = 0.000$	NA	NA
Parmelia <i>et al</i> [27]	> 3.65	ACM	2.696 (1.176–6.181), $P =$	NA	NA	NA	Age, diabetic kidney disease, primary nephrotic condition, arteriovenous fistula vascular access, hemodialysis, respiratory, hemodialysis temperature,

							hematocrit, serum creatinine acid
Wang <i>et al</i> [28]	> 4, < 4	Frailty and ACM	NA	NA	6.530 (3.332–12.798), $P = 0.000$	NA	Age, dialysis duration, education hemoglobin, phosphorus lymphocyte ratio
Zhang <i>et al</i> [29]	< 2.58, > 2.58	ACM and CVM	1.634 (1.023–2.610), $P =$	1.606 (0.854–3.022), $P = 0$	NA	NA	Age, diabetes, coronary artery disease hemoglobin, serum albumin ferritin
He <i>et al</i> [30]	> 3.225	ACM	1.179 (1.053–1.320), $P =$	NA	NA	NA	Age, triglycerides, serum iron binding capacity, serum transferrin urea, serum creatinine


Supplementary Figure 1. Summary Plot of the Risk of Bias Generated using the Robvis Software based on the Joanna Briggs Institute Quality Appraisal of Cohort Studies



This summary plot summarizes the domain-level risk of bias across included studies. Most domains show low risk, though incomplete follow-up and strategies to address it had notable proportions of unclear risk, indicating some methodological limitations in follow-up reporting.

Supplementary Figure 2. Leave-one-out Sensitivity Analysis for NLR >2.5 Association with (A) ACM [HR], (B) CVM [HR], and (C) ACM [OR].


ACM: All-cause Mortality; CVM: Cardiovascular mortality; HR: Hazards ratio; OR: Odds ratio



This figure shows leave-one-out sensitivity analyses for associations between NLR >2.5 and mortality outcomes. Results remain robust across all panels, with no single study significantly altering the pooled effect estimates, indicating the findings are stable


and not driven by any individual study.

Supplementary Figure 3. Scatter plot Illustrating Meta-regression Analysis of Cardiovascular Mortality among Males.



This meta-regression plot shows a significant positive association between the proportion of male participants and the log hazard ratio for cardiovascular mortality (CVM), with a slope of +0.005 and p-value < 0.0001. This suggests that higher male representation may be linked to greater CVM risk associated with elevated NLR.


Supplementary Figure 4. Forest Plot Illustrating Pooled Area Under the Curve - Receiver Operating Curve analysis for All-Cause Mortality



This forest plot displays a pooled rate ratio of 0.71 (95% CI: 0.63–0.80, $p < 0.001$) across six studies, indicating a statistically significant reduction in risk. All individual studies consistently support this finding, with confidence intervals not crossing unity, suggesting robustness in the association analyzed.

Supplementary Figure 5. Funnel Plot Assessment of Publication Bias for NLR Association with (A) ACM and (B) CVM

ACM: All-cause Mortality; CVM: Cardiovascular mortality



These funnel plots assess publication bias. Panel A shows asymmetry, suggesting possible publication bias or small-study effects in the analysis of all-cause mortality. Panel B appears more symmetrical, indicating a lower likelihood of publication bias in the cardiovascular mortality analysis.